Predictors of negotiated prices for new drugs in Germany

INTRODUCTION: In Germany, all new, innovative medicines are subject to an early benefit assessment by the German Federal Joint Committee with subsequent price negotiation and optional arbitration. The purpose of this study was to identify drivers of negotiated (including arbitrated) prices of new, n...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandjour, Afschin, Schüßler, Sofia, Hammerschmidt, Thomas, Dintsios, Charalabos-Markos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423852/
https://www.ncbi.nlm.nih.gov/pubmed/32451745
http://dx.doi.org/10.1007/s10198-020-01201-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423852/
https://www.ncbi.nlm.nih.gov/pubmed/32451745
http://dx.doi.org/10.1007/s10198-020-01201-z

Ejemplares similares